Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
Study Details
Study Description
Brief Summary
The trial is conducted in Europe. The aim of the trial is to investigate the influence of semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of single doses of atorvastatin and digoxin in healthy subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Semaglutide
|
Drug: semaglutide
Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
Drug: digoxin
Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
Drug: atorvastatin
Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
|
Outcome Measures
Primary Outcome Measures
- Area under the atorvastatin plasma concentration-time curve [From time 0 to 72 hours after a single dose]
- Area under the digoxin plasma concentration-time curve [From time 0 to 120 hours after a single dose]
Secondary Outcome Measures
- Maximum observed atorvastatin plasma concentration [From time 0 to 72 hours after a single dose]
- Maximum observed digoxin plasma concentration [From time 0 to 120 hours after a single dose]
- Number of treatment emergent AEs (TEAEs) [From baseline (Visit 2, Day 1) to follow-up (Visit 12, 20 weeks after baseline)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female, age between 18 and 55 years (both inclusive) at the time of signing informed consent
-
Body mass index between 20.0 and 29.9 kg/m^2 (both inclusive)
Exclusion Criteria:
-
Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method. Women of child-bearing potential must use an effective method of birth control throughout the trial including the 5 weeks follow-up period. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or vasectomised partner
-
Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiac, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases
-
Use of prescription or non-prescription systemic or topical medicinal products (including routine or non-routine vitamins or herbal supplements, but excluding paracetamol and contraceptives) within 3 weeks (or within 5 half-lives of the medicinal product, whichever is longest) prior to Visit 2 (first dose administration)
-
History of drug/chemical substance abuse within 1 year from screening, or a positive result in the urine drug test
-
History of alcohol abuse within 1 year from screening, or a positive result in the alcohol urine test, or consumption of more than 21 units (male)/14 units (female) of alcohol weekly (one unit of alcohol equals about 250 mL of beer or lager, one glass (120 mL) of wine, or 20 mL spirits)
-
Smoking in the last 3 months prior to screening or a positive nicotine test
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novo Nordisk Investigational Site | Berlin | Germany | 14050 |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Global Clinical Registry (GCR, 1452), Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- NN9535-3818
- 2013-001288-22
- U1111-1140-8551